SHANGHAI, 10. Juli 2023 /PRNewswire/ — Bioheart (02185.HK) gibt zusammen mit seiner Holding-Tochtergesellschaft Angiocare die klinischen Ergebnisse von Iberis-HTN auf der China Interventional Therapeutics 2023 bekannt. Iberis-HTN ist eine prospektive, multizentrische, verblindete,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.